<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>H.P. ACTHAR- corticotropin injection </strong><br>Mallinckrodt ARD Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use H.P. Acthar<span class="Sup">®</span> Gel safely
      and effectively. See full prescribing information for H.P. Acthar Gel.<br> H.P. Acthar Gel
      (repository corticotropin injection) INJECTION, GEL for INTRAMUSCULAR | SUBCUTANEOUS use<br>
      Initial U.S. Approval: 1952</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disk">
<li>H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue
                              indicated as monotherapy for the treatment of infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> in
                              infants and children under 2 years of age. (<a href="#LINK_b9c41f3d-2a22-4816-a8d2-1a5c58b4a3ed">1.1</a>)</li>
<li>H.P. Acthar Gel is indicated for the treatment of exacerbations of
                              <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> in adults. (<a href="#LINK_19411b91-6e93-4872-b861-0e98f4a9cb4d">1.2</a>)</li>
<li>H.P. Acthar Gel may be used for the following disorders and
                              diseases: rheumatic; collagen; dermatologic; allergic states;
                              ophthalmic; respiratory; and edematous state. (<a href="#LINK_2229cb3d-80e5-476a-a262-1f6490804151">1.3</a> to <a href="#LINK_f8b14b3c-d63b-43af-8cc9-79afc7d6f505">1.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>In the treatment of infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, the recommended dose is 150
                                 U/m<span class="Sup">2</span> divided into twice daily intramuscular injections
                              of 75 U/m<span class="Sup">2</span>. After 2 weeks of treatment, dosing should be
                              gradually tapered and discontinued over a 2-week period. (<a href="#LINK_65507b20-60d9-40ad-848c-e65331af407e">2.1</a>)</li>
<li>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>,
                              daily intramuscular or subcutaneous doses of 80-120 units for 2-3
                              weeks may be administered. It may be necessary to taper the dose.
                                 (<a href="#LINK_811cf5e1-a04d-44f4-877b-e89b1af919a6">2.2</a>)</li>
<li>In the treatment of other disorders and diseases, dosing will need
                              to be individualized depending on the disease under treatment and the
                              medical condition of the patient. It may be necessary to taper the
                              dose. (<a href="#LINK_cbfecc13-4d1e-4915-a128-71a60fe258d8">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li>5 mL multi-dose vial containing 80 USP units per mL (<a href="#LINK_7b7783bf-235f-4126-ae12-9f2d20fe6dcc">3</a>)<br>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li>H.P. Acthar Gel should never be given intravenously.</li>
<li>H.P. Acthar Gel is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>,
                              <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, ocular herpes simplex,
                              recent surgery, history of or the presence of a <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>,
                              <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>, or sensitivity to
                              proteins of porcine origin. </li>
<li>Administration of live or live attenuated vaccines is
                              contraindicated in patients receiving immunosuppressive doses of H.P
                              Acthar Gel.</li>
<li>H.P. Acthar Gel is contraindicated in children under 2 years of age
                              with suspected congenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (<a href="#LINK_37f7460f-fae0-469f-a825-979638b0aad1">4</a>)</li>
<li>Treatment of conditions listed within the INDICATIONS AND USAGE section is
                              contraindicated when they are accompanied by primary adrenocortical
                              insufficiency or adrenocortical hyperfunction. (<a href="#LINK_37f7460f-fae0-469f-a825-979638b0aad1">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Increased susceptibility to new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and increased
                              risk of exacerbation, dissemination or reactivation of latent
                              <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be masked. (<a href="#LINK_6dbd3ede-219b-40cb-94b0-56edd832ed14">5.1</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span> after Prolonged Therapy: Monitor for effects
                              of hypothalamic-pituitary-axis suppression after stopping treatment.
                                 (<a href="#LINK_f6d15c2c-b3fb-4182-9724-9423e6c84a7e">5.2</a>)</li>
<li>Cushing's Syndrome: May occur after prolonged therapy. Monitor for
                              signs and symptoms. (<a href="#LINK_f6d15c2c-b3fb-4182-9724-9423e6c84a7e">5.2</a>)</li>
<li>Elevated Blood Pressure, Salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Water Retention</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>:
                              Monitor blood pressure and sodium and potassium levels. (<a href="#LINK_183d5c59-1db2-43bc-a511-d477e1f90ea4">5.3</a>)</li>
<li>Vaccination: Do not administer live or live attenuated vaccines to
                              patients on immunosuppressive doses. (<a href="#LINK_38a70f78-7183-4af4-a49d-32fee4e8fea1">5.4</a>)</li>
<li>Masking of Symptoms of Other Underlying Disease/Disorders. Monitor
                              patients for signs of other underlying disease/disorders that may be
                              masked. (<a href="#LINK_70c4fb81-8cd3-4c36-96ea-2f6c0c104319">5.5</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: There is a risk for
                              <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. There is an increased risk of perforation
                              in patients with certain GI disorders. Signs and symptoms may be
                              masked. Monitor for signs of perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#LINK_744931a9-146a-42d5-9b87-d0053a61ced5">5.6</a>)</li>
<li>Behavioral and Mood Disturbances: May include <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>,
                              <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.
                              Existing conditions may be aggravated. (<a href="#LINK_52ec13e3-d0f2-4ec8-82fd-22a401d2001a">5.7</a>)</li>
<li>Comorbid Diseases: Symptoms of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> may
                              be worsened with treatment. (<a href="#LINK_717896a0-b70c-45a1-8e54-53eb862ae72e">5.8</a>)</li>
<li>Ophthalmic Effects: Monitor for <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.
                                 (<a href="#LINK_d0a757aa-7fe3-4be0-9afe-29921b882244">5.9</a>)</li>
<li>Immunogenicity Potential: Neutralizing antibodies with chronic
                              administration may lead to a loss of endogenous ACTH activity.
                                 (<a href="#LINK_122bd477-55f2-48ed-9126-1648b53ecc82">5.10</a>)</li>
<li>Use in Patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">Liver Cirrhosis</span>: May result
                              in an enhanced effect. (<a href="#LINK_2ee6b942-3f9e-4b93-8195-e4f4744244d0">5.11</a>)</li>
<li>Negative Effects on Growth and Physical Development: Monitor
                              pediatric patients on long term therapy. (<a href="#LINK_3cea60a7-c124-4375-9db0-648328d58252">5.12</a>)</li>
<li>Decrease in Bone Density: Monitor for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> in patients on
                              long term therapy. (<a href="#LINK_9fdcbcd0-b1ac-4a21-8736-c2288430c453">5.13</a>) </li>
<li>Use in Pregnancy: Embryocidal effect. Apprise women of potential
                              harm to the fetus. (<a href="#LINK_4081c5a8-a565-48d1-9f52-b0e03216e107">5.14</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk">
<li>Common adverse reactions for H.P. Acthar Gel are similar to those
                              of corticosteroids and include <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose
                              tolerance, elevation in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>,
                              <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#LINK_95ff9010-8a8e-4b84-8f63-a5c1a00f467b">6</a>)</li>
<li>Specific adverse reactions resulting from drug use in children
                              under 2 years of age are increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,
                              <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> symptoms, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiac hypertrophy</span> and weight
                              gain. (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mallinckrodt at 1-800-778-7898 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><span class="Italics">www.fda.gov/medwatch</span></span><span class="Bold">.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk"><li>H.P. Acthar Gel may accentuate the electrolyte loss associated with
                              diuretic therapy. (<a href="#LINK_1c0b2b4f-232a-4e66-b3be-5408591bc25c">7</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>Pregnancy: H.P. Acthar Gel has been shown to have an embryocidal
                              effect and should be used during pregnancy only if the potential
                              benefit justifies the potential risk to the fetus. (<a href="#LINK_bb3ef79d-b33d-4176-b89b-b972730e90fe">8.1</a>)</li>
<li>Pediatric Use: Prolonged use of H.P. Acthar Gel in children may
                              inhibit skeletal growth. If use is necessary, it should be given
                              intermittently with careful observation. (<a href="#LINK_3cea60a7-c124-4375-9db0-648328d58252">5.12</a> and <a href="#LINK_273ac1f9-a9c9-41ad-8b26-5c2e573363fb">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>:</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span>:</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Rheumatic Disorders:</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Collagen Diseases:</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 Dermatologic Diseases:</a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Allergic States:</a></h2>
<h2><a href="#section-1.7" class="toc">1.7 Ophthalmic Diseases:</a></h2>
<h2><a href="#section-1.8" class="toc">1.8 Respiratory Diseases:</a></h2>
<h2><a href="#section-1.9" class="toc">1.9 Edematous State:</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Specific Recommended Dosage Regimen for Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span> in Infants
                        and Children Under 2 Years of Age</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dosage Regimen for the Treatment of Acute Exacerbations
                        in Adults with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Recommended Dosage Regimen for Other Indications for Adults and
                        Children Over 2 Years of Age</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Cushing's Syndrome and <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span> Upon Withdrawal</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Elevated Blood Pressure, Salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Water Retention</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Vaccination</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Masking Symptoms of Other Diseases</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Behavioral and Mood Disturbances</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Comorbid Diseases</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Ophthalmic Effects</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Immunogenicity Potential</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Use in Patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">Liver Cirrhosis</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Negative Effects on Growth and Physical Development</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Decrease in Bone Density</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Use in Pregnancy</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.1.1 Adverse Reactions in Infants and Children Under 2 Years of Age</a></h2>
<h2><a href="#section-6.3" class="toc">6.2 Postmarketing Experience</a></h2>
<h2><a href="#section-6.4" class="toc">6.2.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-6.5" class="toc">6.2.2 Cardiovascular</a></h2>
<h2><a href="#section-6.6" class="toc">6.2.3 Dermatologic</a></h2>
<h2><a href="#section-6.7" class="toc">6.2.4 Endocrine</a></h2>
<h2><a href="#section-6.8" class="toc">6.2.5 Gastrointestinal</a></h2>
<h2><a href="#section-6.9" class="toc">6.2.6 Metabolic</a></h2>
<h2><a href="#section-6.10" class="toc">6.2.7 Musculoskeletal</a></h2>
<h2><a href="#section-6.11" class="toc">6.2.8 Neurological</a></h2>
<h2><a href="#section-6.12" class="toc">6.3 Possible Additional Steroidogenic Effects</a></h2>
<h2><a href="#section-6.13" class="toc">6.3.1 Dermatologic</a></h2>
<h2><a href="#section-6.14" class="toc">6.3.2 Endocrine</a></h2>
<h2><a href="#section-6.15" class="toc">6.3.3 Metabolic</a></h2>
<h2><a href="#section-6.16" class="toc">6.3.4 Musculoskeletal</a></h2>
<h2><a href="#section-6.17" class="toc">6.3.5 Neurological</a></h2>
<h2><a href="#section-6.18" class="toc">6.3.6 Ophthalmic</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED / STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_db3dc8de-46fc-4113-99f5-605b73c49266"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="LINK_b9c41f3d-2a22-4816-a8d2-1a5c58b4a3ed"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>:</h2>
<p class="First">H.P. Acthar Gel (repository corticotropin injection) is indicated
                           as monotherapy for the treatment of infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> in infants and
                           children under 2 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_19411b91-6e93-4872-b861-0e98f4a9cb4d"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span>:</h2>
<p class="First">H.P. Acthar Gel (repository corticotropin injection) is indicated
                           for the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> in adults.
                           Controlled clinical trials have shown H.P. Acthar Gel to be effective in
                           speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>.
                           However, there is no evidence that it affects the ultimate outcome or
                           natural history of the disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2229cb3d-80e5-476a-a262-1f6490804151"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Rheumatic Disorders:</h2>
<p class="First"> As adjunctive therapy for short-term administration (to tide the patient
                        over an acute episode or exacerbation) in: <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span>; Rheumatoid
                        <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may
                        require low-dose maintenance therapy), <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b1a1574f-c1f3-4c57-91f5-5fea56c025d4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Collagen Diseases:</h2>
<p class="First">During an exacerbation or as maintenance therapy in selected
                           cases of: <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, systemic <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>
                           (<span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_26f2b5bb-e2b1-44f2-9b3b-23aef3a87144"></a><a name="section-1.5"></a><p></p>
<h2>1.5 Dermatologic Diseases:</h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_747dd67a-55fd-48a3-aebe-eb95f41dfb8c"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Allergic States:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f36cff74-326d-4b1a-ac9f-1ee3e9645c5b"></a><a name="section-1.7"></a><p></p>
<h2>1.7 Ophthalmic Diseases:</h2>
<p class="First">Severe acute and chronic allergic and inflammatory processes
                           involving the eye and its adnexa such as: <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>; <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>,
                           <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>, diffuse posterior <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and choroiditis, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>,
                           <span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">chorioretinitis</span>; anterior segment <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4f1bf756-57bf-4cb6-b5c0-34adf7c1e132"></a><a name="section-1.8"></a><p></p>
<h2>1.8 Respiratory Diseases:</h2>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f8b14b3c-d63b-43af-8cc9-79afc7d6f505"></a><a name="section-1.9"></a><p></p>
<h2>1.9 Edematous State:</h2>
<p class="First">To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or a remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the
                           <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span> of the idiopathic type or that due to
                           <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>. <br></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_b8325f9a-1ed9-4782-b0a7-f4daab2fe7f7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_65507b20-60d9-40ad-848c-e65331af407e"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Specific Recommended Dosage Regimen for Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span> in Infants
                        and Children Under 2 Years of Age</h2>
<p class="First">In the treatment of infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, H.P. Acthar Gel must be
                           administered intramuscularly. The recommended regimen is a daily dose of
                           150 U/m<span class="Sup">2</span> (divided into twice daily intramuscular injections of
                           75 U/m<span class="Sup">2</span>) administered over a 2-week period. Dosing with H.P.
                           Acthar Gel should then be gradually tapered over a 2-week period to avoid
                           <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. The following is one suggested tapering schedule:
                           30 U/m<span class="Sup">2</span> in the morning for 3 days; 15 U/m<span class="Sup">2</span> in the
                           morning for 3 days; 10 U/m<span class="Sup">2</span> in the morning for 3 days; and 10
                              U/m<span class="Sup">2</span> every other morning for 6-days. <br><br>H.P. Acthar
                           Gel is typically dosed based on body surface area (BSA). For calculation
                           of body surface area, use the following formula</p>
<div class="Figure"><img alt="Body Suface Area Calculation" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b48ddec-e815-45f4-9ca0-5c0daaf56f30&amp;name=acthar-1.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_811cf5e1-a04d-44f4-877b-e89b1af919a6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dosage Regimen for the Treatment of Acute Exacerbations
                        in Adults with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></h2>
<p class="First">The recommended dose is daily intramuscular or subcutaneous doses
                           of 80-120 units for 2-3 weeks for acute exacerbations.</p>
<p>Dosage should be individualized according to the medical condition
                           of each patient. Frequency and dose of the drug should be determined by
                           considering the severity of the disease and the initial response of the
                           patient.</p>
<p>Although <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> does not occur, sudden withdrawal of
                           H.P. Acthar Gel after prolonged use may lead to <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or
                           recurrent symptoms which make it difficult to stop the treatment. It may
                           be necessary to taper the dose and increase the injection interval to
                           gradually discontinue the medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cbfecc13-4d1e-4915-a128-71a60fe258d8"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Recommended Dosage Regimen for Other Indications for Adults and
                        Children Over 2 Years of Age</h2>
<p class="First">Dosage should be individualized according to the disease under
                           treatment and the general medical condition of each patient. Frequency
                           and dose of the drug should be determined by considering severity of the
                           disease and the initial response of the patient. </p>
<p>The usual dose of H.P. Acthar Gel is 40-80 units given
                           intramuscularly or subcutaneously every 24-72 hours. </p>
<p>Although <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> does not occur, sudden withdrawal of
                           H.P. Acthar Gel after prolonged use may lead to <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or
                           recurrent symptoms which make it difficult to stop the treatment. It may
                           be necessary to taper the dose and increase the injection interval to
                           gradually discontinue the medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d32cd7ab-e202-4a86-b3a7-10d53ac87822"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation</h2>
<p class="First">H.P. Acthar Gel should be warmed to room temperature before
                           using.</p>
<p>Caution should be taken not to over-pressurize the vial prior to
                           withdrawing the product.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_7b7783bf-235f-4126-ae12-9f2d20fe6dcc"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">5 mL multi-dose vial containing 80 USP Units per mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_37f7460f-fae0-469f-a825-979638b0aad1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">H.P. Acthar Gel is contraindicated for intravenous administration. </p>
<p>H.P. Acthar Gel is contraindicated where congenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are
                     suspected in infants.</p>
<p>Administration of live or live attenuated vaccines is contraindicated
                     in patients receiving immunosuppressive doses of H.P. Acthar Gel.</p>
<p>H.P. Acthar Gel is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>,
                     <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, ocular herpes simplex, recent
                     surgery, history of or the presence of a <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, congestive heart
                     failure, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>, primary adrenocortical insufficiency,
                     adrenocortical hyperfunction or sensitivity to proteins of porcine
                  origin.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_8b9c10ca-02e5-4bcb-b139-a1398e8a01d0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">The adverse effects of H.P. Acthar Gel are related primarily to its
                     steroidogenic effects. Not all of the adverse events described below have been
                     seen after treatment with H.P. Acthar Gel, but might be expected to occur.
                        [<span class="Italics">see Adverse Reactions (<a href="#LINK_4c049260-c6b3-4a96-8823-cb7e400f761a">6.3</a>)</span>]</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6dbd3ede-219b-40cb-94b0-56edd832ed14"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">H.P. Acthar Gel may increase the risks related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with
                           any pathogen, including viral, bacterial, fungal, protozoan or helminthic
                           <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity
                           should be observed closely, and if therapy is prolonged, chemoprophylaxis
                           should be instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f6d15c2c-b3fb-4182-9724-9423e6c84a7e"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Cushing's Syndrome and <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span> Upon Withdrawal</h2>
<p class="First">Treatment with H.P. Acthar Gel can cause
                           hypothalamic-pituitary-axis (HPA) suppression and Cushing's syndrome.
                           These conditions should be monitored especially with chronic use. </p>
<p>Suppression of the HPA may occur following prolonged therapy with
                           the potential for <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> after withdrawal of the
                           medication. Patients should be monitored for signs of insufficiency such
                           as <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and abdominal
                           <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </p>
<p>The symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> in infants treated for
                           infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> can be difficult to identify. The symptoms are
                           non-specific and may include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>,
                           excessive <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. It is critical
                           that parents and caregivers be made aware of the possibility of adrenal
                           insufficiency when discontinuing H.P. Acthar Gel and should be instructed
                           to observe for, and be able to recognize, these symptoms. [<span class="Italics">see Patient Counseling Information </span><span class="Italics"> (<a href="#LINK_223c94bf-1ef6-433e-9554-9311cf36cb09">17</a>)</span>] </p>
<p>The recovery of the adrenal gland may take from days to months so
                           patients should be protected from the stress (e.g. <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or surgery) by
                           the use of corticosteroids during the period of stress.</p>
<p>The <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> may be minimized in adults and infants
                           by tapering of the dose when discontinuing treatment.</p>
<p>Signs or symptoms of Cushing's syndrome may occur during therapy
                           but generally resolve after therapy is stopped. Patients should be
                           monitored for these signs and symptoms such as deposition of adipose
                           tissue in characteristics sites (e.g., <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">truncal obesity</span>),
                           cutaneous <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, easy bruisability, decreased bone mineralization,
                           <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and
                        <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_183d5c59-1db2-43bc-a511-d477e1f90ea4"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Elevated Blood Pressure, Salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Water Retention</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">H.P. Acthar Gel can cause elevation of blood pressure, salt and
                           <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium and calcium.
                           Dietary salt restriction and potassium supplementation may be necessary.
                           Caution should be used in the treatment of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,
                           <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_38a70f78-7183-4af4-a49d-32fee4e8fea1"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Vaccination</h2>
<p class="First">Administration of live or live attenuated vaccines is
                           contraindicated in patients receiving immunosuppressive doses of H.P.
                           Acthar Gel. Killed or inactivated vaccines may be administered; however,
                           the response to such vaccines can not be predicted. Other immunization
                           procedures should be undertaken with caution in patients who are
                           receiving H.P. Acthar Gel, especially when high doses are administered,
                           because of the possible hazards of neurological complications and lack of
                           antibody response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_70c4fb81-8cd3-4c36-96ea-2f6c0c104319"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Masking Symptoms of Other Diseases</h2>
<p class="First">H.P. Acthar Gel often acts by masking symptoms of other
                           diseases/disorders without altering the course of the other
                           disease/disorder. Patients should be monitored carefully during and for a
                           period following discontinuation of therapy for signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>,
                           abnormal cardiac function, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, change in body
                           weight and fecal blood loss.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_744931a9-146a-42d5-9b87-d0053a61ced5"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">H.P. Acthar Gel can cause GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>. There is
                           also an increased risk for perforation in patients with certain
                           <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>. Signs of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, such
                           as peritoneal irritation, may be masked by the therapy. Use caution where
                           there is the possibility of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other
                           pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and
                           active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_52ec13e3-d0f2-4ec8-82fd-22a401d2001a"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Behavioral and Mood Disturbances</h2>
<p class="First">Use of H.P. Acthar Gel may be associated with central nervous
                           system effects ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (especially
                           in infants), <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to
                           frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or
                           <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_717896a0-b70c-45a1-8e54-53eb862ae72e"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Comorbid Diseases</h2>
<p class="First">Patients with a comorbid disease may have that disease worsened.
                           Caution should be used when prescribing H.P. Acthar Gel in patients with
                           <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d0a757aa-7fe3-4be0-9afe-29921b882244"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Ophthalmic Effects</h2>
<p class="First">Prolonged use of H.P. Acthar Gel may produce posterior
                           <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves
                           and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to
                           fungi and viruses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_122bd477-55f2-48ed-9126-1648b53ecc82"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Immunogenicity Potential</h2>
<p class="First">H.P. Acthar Gel is immunogenic. Limited available data suggest
                           that a patient may develop antibodies to H.P. Acthar Gel after chronic
                           administration and loss of endogenous ACTH and H.P. Acthar Gel activity.
                           Prolonged administration of H.P. Acthar Gel may increase the risk of
                           <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Sensitivity to porcine protein should be
                           considered before starting therapy and during the course of treatment
                           should symptoms arise.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2ee6b942-3f9e-4b93-8195-e4f4744244d0"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Use in Patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">Liver Cirrhosis</span></h2>
<p class="First">There is an enhanced effect in patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and
                           in those with cirrhosis of the liver.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3cea60a7-c124-4375-9db0-648328d58252"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Negative Effects on Growth and Physical Development</h2>
<p class="First">Long-term use of H.P. Acthar Gel may have negative effects on
                           growth and physical development in children. Changes in appetite are seen
                           with H.P. Acthar Gel therapy, with the effects becoming more frequent as
                           the dose or treatment period increases. These effects are reversible once
                           H.P. Acthar Gel therapy is stopped. Growth and physical development of
                           pediatric patients on prolonged therapy should be carefully
                        monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9fdcbcd0-b1ac-4a21-8736-c2288430c453"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Decrease in Bone Density</h2>
<p class="First">Decrease in bone formation and an increase in bone resorption
                           both through an effect on calcium regulation (i.e. decreasing absorption and
                           increasing excretion) and inhibition of osteoblast function may occur.
                           These, together with a decrease in the protein matrix of the bone
                           (secondary to an increase in protein catabolism) and reduced sex hormone
                           production, may lead to inhibition of bone growth in children and
                           adolescents and to the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special
                           consideration should be given to patients at increased risk of
                           <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (i.e., postmenopausal
                           women) before initiating therapy, and bone density should be monitored in
                           patients on long term therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4081c5a8-a565-48d1-9f52-b0e03216e107"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Use in Pregnancy</h2>
<p class="First">H.P. Acthar Gel has been shown to have an embryocidal effect.
                           Apprise women of potential harm to the fetus. [<span class="Italics">see Use in Specific Populations (<a href="#LINK_bb3ef79d-b33d-4176-b89b-b972730e90fe">8.1</a>)</span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_95ff9010-8a8e-4b84-8f63-a5c1a00f467b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Please refer to <span class="Italics">Adverse Reactions in Infants and Children Under 2 Years
                     of Age</span> (<span class="Italics"><a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">Section 6.1.1</a></span>) for
                     consideration when treating patients with Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>. The adverse
                     reactions presented in <a href="#LINK_cc5af221-da0e-41c8-b84a-d153b1703451">Section 6.2</a> are primarily provided for consideration in
                     use in adults and in children over 2 years of age, but these adverse reactions
                     should also be considered when treating infants and children under 2 years of
                     age. </p>
<p>H.P. Acthar Gel causes the release of endogenous cortisol from the
                     adrenal gland. Therefore all the adverse effects known to occur with elevated
                     cortisol may occur with H.P. Acthar Gel administration as well. Common adverse
                     reactions include <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose tolerance, elevation
                     in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and weight
                     gain.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_81c25674-3b03-45e5-9dee-239e5134aa02"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying
                           conditions, adverse reaction rates observed in the clinical trials of a
                           drug cannot be directly compared to rates in the clinical trials of
                           another drug, and may not reflect the rates observed in
                        practice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb"></a><a name="section-6.2"></a><p></p>
<h2>6.1.1 Adverse Reactions in Infants and Children Under 2 Years of Age</h2>
<p class="First"> While the types of adverse reactions seen in infants and
                           children under age 2 treated for infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> are similar to those
                           seen in older patients, their frequency and severity may be different due
                           to the very young age of the infant, the underlying disorder, the
                           duration of therapy and the dosage regimen. Below is a summary of adverse
                           reactions specifically tabulated from source data derived from
                           retrospective chart reviews and clinical trials in children under 2 years
                           of age treated for infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>. The number of patients in controlled
                           trials at the recommended dose was too few to provide meaningful
                           incidence rates or to permit a meaningful comparison to the control
                           groups.</p>
<table>
<caption><span> TABLE: Incidence (%) of Treatment Emergent Adverse Events Occurring in ≥ 2% of H.P. Acthar Gel (repository corticotropin injection) Infants
                              and Children under 2 years of Age</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th><span class="Bold">System Organ Class</span></th>
<th>  Recommended<br>75 U/m<span class="Sup">2</span>  bid<br>n=122, (%)<br>
</th>
<th>  150 U/m<span class="Sup">2</span> qd<br>n=37 (%)<br>
</th>
</tr></thead>
<tfoot>
<tr class="First"><td> <span class="Sup">*</span>Specific <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that occurred at
                                    =2% were <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and upper
                                    <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>. </td></tr>
<tr class="Last"><td> <span class="Sup">†</span>In the treatment of
                                    Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>, other types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> may occur
                                    because some patients with infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> progress to other
                                    forms of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (for example, Lennox-Gastaut Syndrome).
                                    Additionally the <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> sometimes mask other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and once
                                    the <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> resolve after treatment, the other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may
                                    become visible. 
                                 </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td> <span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">Cardiac Hypertrophy</span><br>
</td>
<td align="center"> 3</td>
<td align="center"> 0</td>
</tr>
<tr>
<td> <span class="Bold"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span><br></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span><br>
</td>
<td align="center"> 3</td>
<td align="center"> 22</td>
</tr>
<tr>
<td> <span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td align="center"> 0</td>
<td align="center"> 5</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td align="center"> 3</td>
<td align="center"> 14</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td align="center"> 3</td>
<td align="center"> 5</td>
</tr>
<tr>
<td> <span class="Bold">General disorders and administration
                                       site conditions<br></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span><br>
</td>
<td align="center"> 7</td>
<td align="center"> 19</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span><br>
</td>
<td align="center"> 5</td>
<td align="center"> 8</td>
</tr>
<tr>
<td> <span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><span class="Sup">*</span><br>
</td>
<td align="center"> 20</td>
<td align="center"> 46</td>
</tr>
<tr>
<td> <span class="Bold">Investigations</span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span><br>
</td>
<td align="center"> 1</td>
<td align="center"> 3</td>
</tr>
<tr>
<td> <span class="Bold">Metabolism and nutrition
                                       disorders<br></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span><br>
</td>
<td align="center"> 0</td>
<td align="center"> 5</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span><br>
</td>
<td align="center"> 3</td>
<td align="center"> 3</td>
</tr>
<tr>
<td> <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span><span class="Sup">†</span><br>
</td>
<td align="center"> 12</td>
<td align="center"> 3</td>
</tr>
<tr>
<td> <span class="Bold">Respiratory, thoracic and mediastinal
                                       disorders<br></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span><br>
</td>
<td align="center"> 1</td>
<td align="center"> 5</td>
</tr>
<tr>
<td> <span class="Bold">Skin and subcutaneous tissue
                                    disorders</span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></td>
<td align="center"> 0</td>
<td align="center"> 14</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center"> 0</td>
<td align="center"> 8</td>
</tr>
<tr>
<td> <span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>
</td>
<td> <br>
</td>
<td> <br>
</td>
</tr>
<tr class="Last">
<td> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center"> 11</td>
<td align="center"> 19</td>
</tr>
</tbody>
</table>
<p> These adverse reactions may also be seen in adults and children
                        over 2 years of age when treated for other purposes and with different doses
                        and regimens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cc5af221-da0e-41c8-b84a-d153b1703451"></a><a name="section-6.3"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions associated with the use of H.P.
                           Acthar Gel have been identified from postmarketing experience with H.P.
                           Acthar Gel. Only adverse events that are not listed above as adverse
                           events reported from retrospective chart reviews and non-sponsor
                           conducted clinical trials and those not discussed elsewhere in labeling,
                           are listed in this section. Because the adverse reactions are reported
                           voluntarily from a population of uncertain size, it is not always
                           possible to estimate their frequency or establish a causal relationship
                           to use with H.P. Acthar Gel. Events are categorized by system organ
                           class. Unless otherwise noted these adverse events have been reported in
                           infants, children and adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d42fd5cc-1bc7-4250-b3c7-70dad0506d6d"></a><a name="section-6.4"></a><p></p>
<h2>6.2.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Allergic responses have presented as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>
                           (adults only).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9cfa7423-69c9-4392-ab05-a13e8c0fc49a"></a><a name="section-6.5"></a><p></p>
<h2>6.2.2 Cardiovascular</h2>
<p class="First">Necrotizing angitis (adults only) and congestive heart
                        failure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_711b6e93-3ea4-463e-8eb1-9f5506a6e338"></a><a name="section-6.6"></a><p></p>
<h2>6.2.3 Dermatologic</h2>
<p class="First">Skin thinning (adults only), facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and increased
                           <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (adults only).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_540396f4-408e-4854-b5f3-d78d54cd6427"></a><a name="section-6.7"></a><p></p>
<h2>6.2.4 Endocrine</h2>
<p class="First">Decreased carbohydrate tolerance (infants only) and
                        <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f5b98981-266d-46fa-8d0e-9ab57e3339bb"></a><a name="section-6.8"></a><p></p>
<h2>6.2.5 Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> (adults only), abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> and ulcerative
                           <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_25931788-f08f-425e-b62f-b8c837534f2c"></a><a name="section-6.9"></a><p></p>
<h2>6.2.6 Metabolic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">Hypokalemic alkalosis</span> (infants only).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_10caeabc-5026-4758-b2f5-11ea2d190c9a"></a><a name="section-6.10"></a><p></p>
<h2>6.2.7 Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> and vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span> (infants
                           only).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0c030f30-8b5c-44bd-bded-549eeb765e39"></a><a name="section-6.11"></a><p></p>
<h2>6.2.8 Neurological</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (adults only), <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (adults only), <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span>,
                           <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> (adults only), and reversible brain shrinkage
                           (usually secondary to <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) (infants only).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4c049260-c6b3-4a96-8823-cb7e400f761a"></a><a name="section-6.12"></a><p></p>
<h2>6.3 Possible Additional Steroidogenic Effects</h2>
<p class="First">Based on steroidogenic effects of H.P. Acthar Gel certain adverse
                           events may be expected due to the pharmacological effects of
                           corticosteroids. The adverse events that may occur but have not been
                           reported for H.P. Acthar Gel are:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e70c2fe2-e114-48d4-93ad-495675d2e839"></a><a name="section-6.13"></a><p></p>
<h2>6.3.1 Dermatologic</h2>
<p class="First">Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, and
                           suppression of skin test reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_15e8a471-2816-46a0-b0bc-95263b311d92"></a><a name="section-6.14"></a><p></p>
<h2>6.3.2 Endocrine</h2>
<p class="First">Menstrual irregularities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9fbfac12-8847-47de-80d3-afc9edcaf8bf"></a><a name="section-6.15"></a><p></p>
<h2>6.3.3 Metabolic</h2>
<p class="First">Negative nitrogen balance due to protein catabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_37011ab2-3168-4d0f-85ff-cea801d65438"></a><a name="section-6.16"></a><p></p>
<h2>6.3.4 Musculoskeletal</h2>
<p class="First">Loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span> and <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">aseptic necrosis</span> of femoral and humeral
                           heads.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a1d72701-4e3e-446a-acf4-4dbbbad4e3c9"></a><a name="section-6.17"></a><p></p>
<h2>6.3.5 Neurological</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, (pseudo-tumor
                           cerebri) usually after treatment, and subdural <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_711e8a4b-6f69-49ba-b6c3-de52df2dbe8c"></a><a name="section-6.18"></a><p></p>
<h2>6.3.6 Ophthalmic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_1c0b2b4f-232a-4e66-b3be-5408591bc25c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Formal drug-drug interaction studies have not been performed.</p>
<p>H.P. Acthar Gel may accentuate the electrolyte loss associated with
                     diuretic therapy.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_11f51277-3f10-455d-900c-0480e23f4d53"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_bb3ef79d-b33d-4176-b89b-b972730e90fe"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Class C: H.P. Acthar Gel has been shown to have an
                           embryocidal effect. There are no adequate and well-controlled studies in
                           pregnant women. H.P. Acthar Gel should be used during pregnancy only if
                           the potential benefit justifies the potential risk to the
                        fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_633d7a8c-ccdd-4b0b-85de-4fbaed46c298"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk.
                           Because many drugs are excreted in human milk and because of the
                           potential for serious adverse reactions in nursing infants from H.P.
                           Acthar Gel, when treating a nursing mother, a decision should be made
                           whether to discontinue nursing or to discontinue the drug, considering
                           the risk and benefit to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_273ac1f9-a9c9-41ad-8b26-5c2e573363fb"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">H.P. Acthar Gel is indicated as monotherapy for the treatment of
                           infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> in infants and children less than 2 years of age. Both
                           serious and other adverse reactions in this population are discussed in
                           Warnings and Adverse Reactions in Infants and Children Under 2 Years of
                           Age [<span class="Italics">see Sections <a href="#LINK_8b9c10ca-02e5-4bcb-b139-a1398e8a01d0">5</a> and <a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a></span>]. </p>
<p>The efficacy of H.P. Acthar Gel for the treatment of infantile
                           <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> in infants and children less than 2 years of age was evaluated in
                           a randomized, single blinded (video EEG interpreter blinded) clinical
                           trial and an additional active control supportive trial [<span class="Italics">see Clinical Studies (<a href="#LINK_d46e8d49-1194-4604-89d4-9a4f930e41fb">14</a>)</span>]. A responding patient was defined as
                           having both complete cessation of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> and elimination of
                           hypsarrhythmia. </p>
<p>Safety in the pediatric population for infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> was
                           evaluated by retrospective chart reviews and data from non-sponsor
                           conducted clinical trials [<span class="Italics">see Adverse
                              Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>]. While the types of adverse reactions seen
                           in infants and children under 2 years of age treated for infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>
                           are similar to those seen in older patients, their frequency and severity
                           may be different due to the very young age of the infant, the underlying
                           disorder, the duration of therapy and the dosage regimen. Effects on
                           growth are of particular concern [<span class="Italics">see
                              Warnings and Precautions (<a href="#LINK_3cea60a7-c124-4375-9db0-648328d58252">5.12</a>)</span>]. Serious adverse reactions observed in
                           adults may also occur in children [<span class="Italics">see
                              Warnings and Precautions (<a href="#LINK_8b9c10ca-02e5-4bcb-b139-a1398e8a01d0">5</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_491fa0f5-ade2-4ebb-b299-b96c9c8c3b4e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">While chronic exposure to H.P. Acthar Gel at high doses can be
                     associated with a variety of potential serious adverse effects, it is not
                     expected that a single high dose, or even several large doses, has the
                     potential for serious adverse effects compared to a standard dose. There have
                     been no reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> symptoms from H.P. Acthar Gel in
                     clinical studies or in the published literature.</p>
<p>The intramuscular route of administration makes it unlikely that an
                     inadvertent <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> will occur. The typical daily dose of H.P. Acthar
                     Gel to treat an infant that has a BSA of 0.4 m<span class="Sup">2</span> would be 60 U/day.
                     Using the 1-cc syringe supplied with H.P. Acthar Gel, the maximum amount that
                     can be injected is 80 U/injection, which is a well-tolerated single
                  dose.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_31597c98-139d-49c2-a59c-6581e50cfa14"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">H.P. Acthar Gel is a highly purified sterile preparation of the
                     adrenocorticotropic hormone in 16% gelatin to provide a prolonged release after
                     intramuscular or subcutaneous injection. Also contains 0.5% phenol, not more
                     than 0.1% cysteine (added), sodium hydroxide and/or acetic acid to adjust pH
                     and water for injection. </p>
<p>ACTH is a 39 amino acid peptide with the following chemical formula: </p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> H-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Ser-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Tyr-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Ser-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Met-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Glu-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> His-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Phe-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Arg-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Trp-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Gly-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 6</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 7</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 9</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Lys-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Pro-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Val-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Gly-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Lys-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Lys-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Arg-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Arg-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Pro-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Val-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 11</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 12</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 13</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 14</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 17</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 18</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 19</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Lys-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Val-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Try-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Pro-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Asp-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Gly-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Ala-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Glu-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Asp-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Gln-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 21</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 22</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 23</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 24</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 25</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 26</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 27</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 28</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 29</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 30</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Leu-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Ala-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Glu-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Ala-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Phe-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Pro-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Leu-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Glu-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Phe-</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> OH-</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 31</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 32</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 33</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 34</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 35</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 36</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 37</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 38</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 39</td>
</tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fdbf344d-9085-4ddd-a416-dea1dacb4b5d"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_98ae89bf-ba03-45de-8e6d-57ad3dc36eb3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of H.P. Acthar Gel in the treatment of
                           infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> is unknown.</p>
<p>H.P. Acthar Gel and endogenous ACTH stimulate the adrenal cortex
                           to secrete cortisol, corticosterone, aldosterone, and a number of weakly
                           androgenic substances. Prolonged administration of large doses of H.P.
                           Acthar Gel induces <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> of the adrenal cortex and
                           continuous high output of cortisol, corticosterone and weak <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.
                           The release of endogenous ACTH is under the influence of the nervous
                           system via the regulatory hormone released from the hypothalamus and by a
                           negative corticosteroid feedback mechanism. Elevated plasma cortisol
                           suppresses ACTH release.</p>
<p>H.P. Acthar Gel is also reported to bind to melanocortin
                           receptors.</p>
<p>The trophic effects of endogenous ACTH and H.P. Acthar Gel on the
                           adrenal cortex are not well understood beyond the fact that they appear
                           to be mediated by cyclic AMP. </p>
<p>ACTH rapidly disappears from the circulation following its
                           intravenous administration; in people, the plasma half-life is about 15
                           minutes. The pharmacokinetics of H.P. Acthar Gel have not been adequately
                           characterized. </p>
<p>The maximal effects of a trophic hormone on a target organ are
                           achieved when optimal amounts of hormone are acting continuously. Thus, a
                           fixed dose of H.P. Acthar Gel will demonstrate a linear increase in
                           adrenocortical secretion with increasing duration for the
                        infusion.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_f7cc4448-78ac-40cd-8011-8409750c907e"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_1e7dcd19-dfe5-4914-b5e2-3885c6e073b9"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Adequate and well-controlled studies have not been done in
                           animals. Human use has not been associated with an increase in malignant
                           disease. [<span class="Italics">see Warnings and Precautions
                                 (<a href="#LINK_4081c5a8-a565-48d1-9f52-b0e03216e107">5.14</a>) </span><span class="Italics">and </span><span class="Italics">Use in Specific Populations (<a href="#LINK_bb3ef79d-b33d-4176-b89b-b972730e90fe">8.1</a>)</span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_d46e8d49-1194-4604-89d4-9a4f930e41fb"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The effectiveness of H.P. Acthar Gel as a treatment for infantile
                     <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> was demonstrated in a single blinded (video EEG interpreter blinded)
                     clinical trial in which patients were randomized to receive either a 2 week
                     course of treatment with H.P. Acthar Gel (75 U/m<span class="Sup">2</span> intramuscular
                     twice daily) or prednisone (1 mg/kg by mouth twice daily). The primary outcome
                     was a comparison of the number of patients in each group who were treatment
                     responders, defined as a patient having complete suppression of both clinical
                     <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> and hypsarrhythmia on a full sleep cycle video EEG performed 2 weeks
                     following treatment initiation, rated by an investigator blinded to treatment.
                     Thirteen of 15 patients (86.7%) responded to H.P. Acthar Gel as compared to 4
                     of 14 patients (28.6%) given prednisone (p&lt;0.002). The 2-week treatment
                     was followed by a 2-week period of taper. Nonresponders to the prednisone
                     treatment were eligible to receive H.P. Acthar Gel treatment. Seven of 8
                     patients (87.5%) responded to H.P. Acthar Gel after not responding to
                     prednisone. Similarly, the 2 nonresponder patients from the H.P. Acthar Gel
                     treatment were eligible to receive treatment with prednisone. One of the 2
                     patients (50%) responded to the prednisone treatment after not responding to
                     H.P. Acthar Gel.</p>
<p> A supportive single-blind, randomized clinical trial comparing
                     high-dose, long-duration treatment (150 U/m<span class="Sup">2</span> once daily for 3 weeks,
                     n=30) of H.P. Acthar Gel with low-dose, short-duration treatment (20 U once
                     daily for 2 weeks, n=29) for the treatment of infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> was also
                     evaluated in infants and children less than 2 years of age. Nonresponders
                     (defined as in the previously described study) in the low-dose group received a
                     dose escalation at 2 weeks to 30 U once daily. Nominal statistical superiority
                     of the high dose treatment, as compared to the low dose treatment, was observed
                     for cessation of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> but not for the resolution of hypsarrhythmia.
                  </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_be558d2e-6148-43c5-a952-8bae19aa0fc5"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED / STORAGE AND HANDLING</h1>
<p class="First">H.P. Acthar Gel (repository corticotropin injection) is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection) should be warmed to room temperature before using. Do not over pressurize the vial prior to withdrawing the product.</p>
<p>Store H.P. Acthar Gel (repository corticotropin injection) under refrigeration between 2° to 8°C (36° to 46°F). Product is stable for the period indicated on the label when stored under the conditions described.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_223c94bf-1ef6-433e-9554-9311cf36cb09"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Caretakers of patients with infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> should be informed of the
                     availability of a Medication Guide, and they should be instructed to read the
                     Medication Guide prior to administering H.P. Acthar Gel. Patients should be
                     instructed to take H.P. Acthar Gel only as prescribed. They should not stop
                     treatment suddenly unless instructed by their physician to do so. </p>
<p>Patients, their caregivers and families should be advised as to the
                     importance of the need for careful monitoring while on and during titration
                     from H.P. Acthar Gel treatment and the importance of not missing scheduled
                     doctor’s appointments. </p>
<p>Patients, their caregivers and families should be advised that if the
                     patient develops an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> they should contact their physician.
                     They should be educated that a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> may not necessarily be present during
                     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The patient should also try to limit contact with other people with
                     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> to minimize the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while taking H.P. Acthar Gel.
                        [<span class="Italics">see Warnings and Precautions (<a href="#LINK_6dbd3ede-219b-40cb-94b0-56edd832ed14">5.1</a>) </span><span class="Italics">and Adverse Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>]</p>
<p> Patients, their caregivers and families should be advised that if the
                     patient experiences an increase in blood pressure they should contact their
                     physician. [<span class="Italics">see Warnings and Precautions
                           (<a href="#LINK_183d5c59-1db2-43bc-a511-d477e1f90ea4">5.3</a>) </span><span class="Italics">and Adverse Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>] </p>
<p>Patients, their caregivers and families should be advised that if the
                     patient or the caregiver notices blood or a change in color of the patient’s
                     stool they should contact their physician. [<span class="Italics">see
                        Warnings and Precautions (<a href="#LINK_744931a9-146a-42d5-9b87-d0053a61ced5">5.6</a>)</span>]</p>
<p>Caregivers and families of infants and children treated with H.P.
                     Acthar Gel should be informed that the patient may show signs of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>
                     and <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span>. These effects are reversible once H.P. Acthar Gel
                     therapy is stopped. [<span class="Italics">see Warnings and Precautions
                           (<a href="#LINK_52ec13e3-d0f2-4ec8-82fd-22a401d2001a">5.7</a>) </span><span class="Italics">and Adverse Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>]</p>
<p> Patients, their caregivers and families should be advised that changes
                     in appetite, most often leading to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, are seen with H.P. Acthar Gel
                     therapy, becoming more frequent as the dose or treatment period increases.
                     These effects are reversible once H.P. Acthar Gel therapy is stopped. [<span class="Italics">see Warnings and Precautions (<a href="#LINK_3cea60a7-c124-4375-9db0-648328d58252">5.12</a>) </span><span class="Italics">and Adverse Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>]</p>
<p>Patients, their caregivers and families should be advised that the
                     patient may be monitored for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> such as <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>,
                     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or
                     hyperpigmentation (adults only) after treatment has stopped. Since the recovery
                     of the adrenal gland varies from days to months, patients may need to be
                     protected from the stress of <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or surgery by the use of corticosteroids
                     during the period of stress. [<span class="Italics">see Warnings and
                        Precautions (<a href="#LINK_f6d15c2c-b3fb-4182-9724-9423e6c84a7e">5.2</a>)</span>]</p>
<p>Patients should be advised not to be vaccinated with live or live
                     attenuated vaccines during treatment with H.P. Acthar Gel. Additionally, other
                     immunization procedures in patients or in family members who will be in contact
                     with the patient should be undertaken with caution while the patient is taking
                     H.P. Acthar Gel. [<span class="Italics">see Warnings and Precautions
                           (<a href="#LINK_38a70f78-7183-4af4-a49d-32fee4e8fea1">5.4</a>)</span>]</p>
<p>Patients, their caregivers and families should be advised that
                     prolonged use of H.P. Acthar Gel in children may result in Cushing’s syndrome
                     and associated adverse reactions, may inhibit skeletal growth, and may cause
                     <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and decreased bone density. If prolonged use is necessary, H.P.
                     Acthar Gel should be given intermittently along with careful observation.
                        [<span class="Italics">see Warnings and Precautions (<a href="#LINK_f6d15c2c-b3fb-4182-9724-9423e6c84a7e">5.2</a>), (<a href="#LINK_3cea60a7-c124-4375-9db0-648328d58252">5.12</a>), and (<a href="#LINK_9fdcbcd0-b1ac-4a21-8736-c2288430c453">5.13</a>) </span><span class="Italics">and Adverse Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>]</p>
<p>Patients, their caregivers and families should be informed that H.P. Acthar
                     Gel may mask symptoms of other diseases/disorders without altering the course
                     of the other disease/disorder. The patient will need to be monitored carefully
                     during and for a period following discontinuation of therapy for signs of
                     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, abnormal cardiac function, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, change in
                     body weight, and fecal blood loss. [<span class="Italics">see Warnings
                        and Precautions (<a href="#LINK_70c4fb81-8cd3-4c36-96ea-2f6c0c104319">5.5</a>)</span>]</p>
<p> In the treatment of Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>, other types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may
                     occur because some patients with infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> progress to other forms of
                     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (for example, Lennox-Gastaut Syndrome). Additionally the <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>
                     sometimes mask other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and once the <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> resolve after treatment with
                     H.P. Acthar Gel, the other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may become visible. Parents and caregivers
                     should inform their physician of any new onset of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> so that appropriate
                     management can then be instituted. [<span class="Italics">see Adverse
                        Reactions (<a href="#LINK_7853dc08-dbfb-4659-9ce1-9428f55bc1bb">6.1.1</a>)</span>]                  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_afad2e80-c44b-43fe-b3b4-0316bf7328f2"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First">Mallinckrodt, the “M? brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.  </p>
<p>© 2015 Mallinckrodt.</p>
<p>Manufactured for: </p>
<p>Mallinckrodt ARD Inc.</p>
<p>Hazelwood, MO 63042 USA</p>
<p>PL065</p>
<p>Rev 01/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="LINK_64e75d7c-0c68-44fd-9e5a-3fcc2f403283"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">H.P. Acthar® Gel (H P AK-thar
                        jel)<br>(repository corticotropin Injection)</span></p>
<p><span class="Bold"> </span><span class="Bold">This Medication Guide provides information
                        only about the use of H.P. Acthar Gel for the treatment of Infantile
                     <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>.</span> If your doctor prescribes H.P. Acthar Gel for you or your
                     child for any other reason, talk to your doctor for information about how this
                     medicine is used to treat your medical condition.</p>
<p> Read this Medication Guide before your child receives H.P Acthar Gel
                     and each time you refill your child’s prescription. There may be new
                     information. This Medication Guide does not take the place of talking with your
                     doctor about your child’s medical condition or treatment.</p>
<p><span class="Bold"> </span><span class="Bold">What is the most important information I should know
                        about H.P. ACTHAR GEL?</span></p>
<p><span class="Bold"> </span><span class="Bold">H.P. Acthar Gel can cause serious side effects
                        including:</span></p>
<p><span class="Bold">1. Increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span>
                     H.P Acthar Gel is a medicine that can affect your child’s immune system. When
                     your child is taking H.P. Acthar Gel, it can lower the ability of your child’s
                     immune system to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. H.P. Acthar Gel may:</p>
<ul class="Disc">
<li>make your child more likely to get new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
<li>worsen an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that your child already has</li>
<li>cause an inactive <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to become active, such as <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB)</li>
</ul>
<p> Before starting H.P. Acthar Gel, tell your doctor if your child has:</p>
<ul class="Circle">
<li>an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or signs of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, such as:
                        <ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>other signs of flu or illness</li>
</ul>
</li>
<li>a family member with an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or signs of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </li>
</ul>
<p> While taking H.P. Acthar Gel, your child should:</p>
<ul class="Circle">
<li>stay away from people who are sick or who have <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
<li>tell your doctor right away if your child has any sign of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as:</li>
</ul>
<ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (but your child may not have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> with an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or</li>
<li>other signs of illness or flu and</li>
<li>any open cuts or sores on his or her body</li>
</ul>
<p><span class="Bold"> </span><span class="Bold">2. Effects on the adrenal gland after stopping H.P.
                        Acthar Gel.</span></p>
<p> When your child stops taking H.P. Acthar Gel, his or her body may not
                     produce enough of a hormone called cortisol on its own (<span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>).
                     Your child may need to take steroid medicine to protect the body until the
                     adrenal gland recovers and is working well again, especially to protect the
                     body if they have surgery or <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. <span class="Bold">Do not stop
                        giving your child injections of H.P. Acthar Gel without talking to your
                        doctor first.</span> Your doctor will tell you when and how to slowly
                     stop giving the injections to avoid serious side effects.</p>
<p><span class="Bold"> </span><span class="Bold">While slowly stopping your child’s injections of H.P.
                        Acthar Gel or after you stop giving the injections, call your doctor right
                        away if your child has any of the following:</span></p>
<ul class="Disc">
<li>appears weak</li>
<li>loses weight or has a decrease in appetite</li>
<li>appears tired or lacking energy</li>
<li>appears <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span></li>
<li>has <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>appears sick or is with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
</ul>
<p><span class="Bold"> </span><span class="Bold">3. Effects on the adrenal gland while taking H.P.
                        Acthar Gel </span></p>
<p> When your child is taking H.P. Acthar Gel, his or her adrenal gland may
                     produce too much cortisol. This can cause symptoms of Cushing’s syndrome.
                     Cushing’s syndrome is more common in children who take H.P. Acthar Gel for a
                     long time.</p>
<p> Symptoms of Cushing’s syndrome include:</p>
<ul class="Disc">
<li>increased upper body fat around the neck, but not the arms and legs</li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> </li>
<li>rounded or “moon? face</li>
<li>thin skin, easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, and stretch marks on thighs, belly and trunk</li>
<li>slowed growth rates in children</li>
<li>weak bones (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>) </li>
</ul>
<p> While receiving treatment with H.P. Acthar Gel other side effects can
                     happen that are like side effects that happen due to treatment with steroid
                     medicines. The risk of getting side effects may increase the longer your child
                     is treated with H.P. Acthar Gel. Side effects may include:</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>. </span>Your doctor may check your child’s blood pressure during treatment. If your child’s blood pressure increases, your doctor may talk with you about possible treatment choices. </li>
<li>
<span class="Bold">too much water in the body (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>), increased amount of body salts, and low potassium in the blood. </span>H.P. Acthar Gel may cause your child to have an increased amount of body salts and water that stays in the body, and may lower the amount of potassium in your child’s blood. Follow your doctor’s instructions about if you need to decrease your child’s salt intake or if you need to feed your child foods high in potassium.</li>
</ul>
<p><span class="Bold"> </span><span class="Bold">4. Your child should not receive certain
                        vaccines during treatment with H.P. Acthar Gel.</span>Your child may
                     receive killed or inactivated vaccines while receiving H.P. Acthar Gel. Before
                     your child receives any vaccines, talk to your doctor about which vaccines are
                     safe for your child. Certain vaccines could cause your child to have serious
                     side effects, or the vaccine may not be effective.</p>
<p><span class="Bold"> </span><span class="Bold">5. Hiding (masking) symptoms of other
                        conditions or diseases.</span>It may be more difficult for your doctor to
                     diagnose other conditions or diseases in your child during treatment with H.P.
                     Acthar Gel. During treatment and after treatment ends, tell your doctor if your
                     child has:</p>
<ul class="Disc">
<li>any signs or symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. See number 1 of this section in the Medication Guide.</li>
<li>changes in body weight</li>
<li>bloody or black tarry stool</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>excessive <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span></li>
<li>fast heart rate</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span></li>
</ul>
<p><span class="Bold"> </span><span class="Bold">6. Stomach and intestinal problems. H.P.
                        Acthar Gel may cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of the stomach or intestine.</span> Your
                     child has an increased risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the stomach or having a stomach
                     <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>. Tell your doctor if your child has any <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the stomach area
                     (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), vomits blood, or has bloody or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span>.</p>
<p><span class="Bold"> </span><span class="Bold">7. Changes in mood and
                     behavior.</span>During treatment with H.P. Acthar Gel your child may be
                     <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span>, have rapid changes in his or her mood, be depressed, have other
                     changes in his or her behavior, or have trouble sleeping.</p>
<p><span class="Bold"> </span><span class="Bold">Tell your doctor if your child has any of the side
                        effects or symptoms listed above.</span></p>
<p><span class="Bold"> </span><span class="Bold">What is H.P. ACTHAR GEL?</span><br>H.P.
                     Acthar Gel is a prescription medicine that is used to treat infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> in
                     infants and children under 2 years of age. </p>
<p><span class="Bold"> </span><span class="Bold">What should I tell my doctor before my child takes
                        H.P. ACTHAR GEL?</span></p>
<p> Before your child takes H.P. Acthar Gel, read the section above “What
                     is the most important information I should know about H.P. Acthar Gel?? and
                     tell your doctor if your child has:</p>
<ul class="Disc">
<li>an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></li>
<li>heart problems</li>
<li>kidney problems</li>
<li>stomach or intestinal problems</li>
<li>thyroid problems</li>
<li>liver problems</li>
<li>neuromuscular problems</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li>had exposure to someone with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> (TB)</li>
<li>a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or trouble breathing, to H.P. Acthar Gel or pork products</li>
<li>had recent surgery</li>
<li>had a recent vaccination or is scheduled to receive a vaccination</li>
<li>a family member who is receiving vaccinations</li>
</ul>
<p> Tell your doctor about all the medicines your child takes, including
                     prescription and non-prescription medicines, vitamins and herbal supplements.
                     Do not start giving a new medicine to your child without first speaking to your
                     doctor.</p>
<p><span class="Bold">  </span><span class="Bold">How should I give H.P. Acthar Gel to my
                        child?</span> H.P. Acthar Gel is given as an injection into the muscle.
                     Do not inject it under the skin, into a vein, or give it to your child by
                     mouth.</p>
<ul class="Disc">
<li>Inject H.P. Acthar Gel exactly as your doctor tells you. Your doctor will tell you where to give the injection, how much to give, how often and when to give it to your child.</li>
<li>Do not use H.P. Acthar Gel until your doctor has taught you how to give the injection to your child.</li>
<li>To give H.P. Acthar Gel:<ul class="Circle">
<li>Take the bottle from the refrigerator. Do not open the bottle or pry the cap (rubber stopper) off.</li>
<li>Warm the contents by rolling the bottle between your hands for a few minutes.</li>
<li>Wash your hands.</li>
<li>Prepare the skin where you are going to give the injection by wiping it with a new sterile alcohol wipe. Before giving the injection, look at the site prepared for the injection and make sure that it no longer looks wet. A wet site can cause burning.</li>
<li>Wipe the top of the vial rubber stopper with a new sterile alcohol wipe. </li>
<li>Use a new sterile needle and syringe to draw up the amount of H.P. Acthar Gel the doctor has told you to use.</li>
<li>Give the injection the way the doctor has instructed you.</li>
<li>Return the bottle to the refrigerator as soon as possible.</li>
</ul>
</li>
</ul>
<ul class="Disc">
<li>
<span class="Bold">Keep all of your child’s follow-up appointments with your doctor</span><p class="First"><span class="Bold"> </span></p>
</li>
<li>It is important for you to tell your doctor if your child’s <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> continue or change in any way during treatment or after treatment has stopped so that they can monitor your child’s progress.</li>
</ul>
<p><span class="Bold"> </span><span class="Bold">Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span> sometimes hides (masks) other
                        <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> your child or infant may have. Once treated with H.P. Acthar Gel,
                        the Infantile <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span> symptoms may disappear. This may allow the other
                        <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> to become visible for the first time. Tell your child’s doctor
                        right away if you see a change in your child’s <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>.</span></p>
<p><span class="Bold"> </span><span class="Bold">What are the possible side effects of H.P. Acthar
                        Gel?</span></p>
<p><span class="Bold">H.P Acthar Gel can cause serious side effects.</span></p>
<ul class="Disk">
<li><span class="Bold">See “What is the most important information I
                           should know about H.P. Acthar Gel.?</span></li>
<li><span class="Bold">H.P. Acthar Gel may make certain other medical
                           conditions worse, such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (may increase blood sugar).</span></li>
<li>
<span class="Bold">Eye problems.</span>Your child can get
                        <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, increased pressure in the eye (<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>), and possible damage to
                        the optic nerve if treated with H.P. Acthar Gel for a long time.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> to H.P. Acthar
                        Gel.</span>Your child may have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to H.P. Acthar Gel.
                        <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may not happen until your child has received several
                        injections of H.P. Acthar Gel. Tell your doctor right away if your child has any of the following  signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>: 
                        <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, tongue, lips, or throat</li>
<li>trouble breathing</li>
</ul>
</li>
<li>
<span class="Bold">Changes in growth and physical
                        development.</span>H.P. Acthar Gel may affect your child’s growth and
                        physical development and may weaken his or her bones. This is more likely to
                        happen with long term use of H.P. Acthar Gel. </li>
<li>
<span class="Bold">Enlarged heart.</span> H.P. Acthar Gel may
                        cause an increase in the size of your child’s heart. This is more likely to
                        happen with long term use of H.P. Acthar Gel but usually goes away after
                        H.P. Acthar Gel is stopped.</li>
</ul>
<p><span class="Bold"> </span><span class="Bold">Common side effects of H.P. Acthar Gel may include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
<li><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span></li>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and changes in behavior</li>
<li>changes in appetite and weight</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p> These are not all the possible side effects of H.P. Acthar Gel. Tell
                     your doctor if your child has any side effect that bothers them or does not go
                     away. For more information ask your child’s doctor or pharmacist.</p>
<p> Call your doctor for medical advice about side effects. You may report
                     side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold"> </span><span class="Bold">How should I store H.P. ACTHAR GEL?</span></p>
<ul class="Disk">
<li>Store vials of H.P. Acthar Gel in the refrigerator between 36°F
                        to 46°F (2°C to 8°C).</li>
<li>Throw away any vials after the expiration date printed on the
                     label.</li>
</ul>
<p><span class="Bold"> </span><span class="Bold">Keep H.P. Acthar Gel and all other medicines out of
                        the reach of children </span></p>
<p><span class="Bold"> </span><span class="Bold">General information About H.P. Acthar
                     Gel</span><br>Medicines are sometimes prescribed for purposes other than
                     those listed in a Medication Guide. Do not use H.P. Acthar Gel for a condition
                     for which it has not been prescribed. Do not give H.P. Acthar Gel to other
                     people, even if they have the same symptoms. It may harm them.</p>
<p> This Medication Guide summarizes the most important information about
                     H.P. Acthar Gel. If you would like more information, talk with your child’s
                     doctor. You can ask your child’s doctor or pharmacist for information about
                     H.P. Acthar Gel that is written for healthcare professionals. For more
                     information, go to www.acthar.com or
                     call 1-800-778-7898.</p>
<p><span class="Bold"> </span><span class="Bold">What are the ingredients in H.P. Acthar
                        Gel?</span><span class="Bold"><br></span><span class="Bold">Active ingredient: </span>Corticotropin<br><span class="Bold">Inactive ingredients: </span>gelatin, phenol, cysteine,
                     sodium hydroxide and/or acetic acid to adjust pH, and water for injection</p>
<p> Manufactured for:</p>
<p>Mallinckrodt ARD Inc.</p>
<p>Hazelwood, MO 63042 USA</p>
<p> PL122  Rev 01/2015 </p>
<p> This Medication Guide has been approved by the U.S. Food and Drug
                     Administration.</p>
<p> Mallinckrodt, the “M? brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. </p>
<p>© 2015 Mallinckrodt.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_d895afa0-6826-4685-ab14-07ea488f0646"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 5 mL CARTON</span></p>
<p><span class="Bold">NDC 63004-8710-1</span></p>
<p><span class="Bold">H.P.* Acthar<span class="Sup">® </span>Gel</span></p>
<p>(repository corticotropin injection)</p>
<p><span class="Bold">400 USP units/5 mL</span><br>(80 USP units/mL)</p>
<p>For intramuscular or subcutaneous use.</p>
<p>5 mL multiple-dose vial</p>
<p>Dispense the enclosed Medication Guide to each Infantile Spasm patient </p>
<p><span class="Bold">R<span class="Sub">x</span></span> only    *<span class="Bold">HIGHLY PURIFIED</span></p>
<p>PL064 Rev 01/2015</p>
<div class="Figure"><img alt="5 mL carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b48ddec-e815-45f4-9ca0-5c0daaf56f30&amp;name=acthar-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>H.P. ACTHAR 		
					</strong><br><span class="contentTableReg">repository corticotropin injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63004-8710</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CORTICOTROPIN</strong> (CORTICOTROPIN) </td>
<td class="formItem">CORTICOTROPIN</td>
<td class="formItem">80 [USP'U]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CYSTEINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63004-8710-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA008372</td>
<td class="formItem">01/07/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mallinckrodt ARD Inc.
							(625130828)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene bioPharma Inc.</td>
<td class="formItem"></td>
<td class="formItem">050783398</td>
<td class="formItem">MANUFACTURE(63004-8710)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>93e5c7ab-c031-4ee7-a997-20d3e0b086a5</div>
<div>Set id: 7b48ddec-e815-45f4-9ca0-5c0daaf56f30</div>
<div>Version: 3</div>
<div>Effective Time: 20150121</div>
</div>
</div> <div class="DistributorName">Mallinckrodt ARD Inc.</div></p>
</body></html>
